Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, Guangdong Province, China.
Department of Nuclear Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, Guangdong Province, China.
World J Gastroenterol. 2024 Sep 28;30(36):4071-4077. doi: 10.3748/wjg.v30.i36.4071.
Surgical resection and liver transplantation (LT) are the most effective curative options for hepatocellular carcinoma (HCC). However, few patients with huge HCC (> 10 cm in diameter), especially those with portal vein tumor thrombus (PVTT), can receive these treatments. Selective internal radiation therapy (SIRT) can be used as a conversion therapy for them because it has the dual benefit of shrinking tumors and increasing residual hepatic volume. However, in patients with huge HCC, high lung absorbed dose often prevents them from receiving SIRT.
A 35-year-old man was admitted because of emaciation and pain in the hepatic region for about 1 month. The computed tomography scan showed a 20.2 cm × 19.8 cm tumor located in the right lobe-left medial lobes with right portal vein and right hepatic vein invasion. After the pathological type of HCC was confirmed by biopsy, two conversions were presented. The first one was drug-eluting bead transarterial chemoembolization plus hepatic arterial infusion chemotherapy and lenvatinib and sintilimab, converted to SIRT, and the second one was sequential SIRT with continued systemic treatment. The tumor size significantly decreased from 20.2 cm × 19.8 cm to 16.2 cm × 13.8 cm, then sequentially to 7.8 cm × 6.8 cm. In the meantime, the ratio of spared volume to total liver volume increased gradually from 34.4% to 55.7%, then to 62.9%. Furthermore, there was visualization of the portal vein, indicating regression of the tumor thrombus. Finally, owing to the new tumor in the left lateral lobe, the patient underwent LT instead of resection without major complications.
Patients with inoperable huge HCC with PVTT could be converted to SIRT first and accept surgery sequentially.
手术切除和肝移植(LT)是治疗肝细胞癌(HCC)最有效的方法。然而,很少有巨大 HCC(直径>10cm)的患者,特别是伴有门静脉癌栓(PVTT)的患者,可以接受这些治疗。选择性内放射治疗(SIRT)可作为转化治疗,因为它具有缩小肿瘤和增加剩余肝体积的双重益处。然而,在巨大 HCC 患者中,高肺吸收剂量常使他们无法接受 SIRT。
一名 35 岁男性因消瘦和肝区疼痛约 1 个月入院。CT 扫描显示位于右叶-左内侧叶的 20.2cm×19.8cm 肿瘤,伴有右门静脉和右肝静脉侵犯。经活检证实 HCC 病理类型后,提出了两种转化治疗方案。第一种方案是载药微球经动脉化疗栓塞术加肝动脉灌注化疗和仑伐替尼联合信迪利单抗,转化为 SIRT;第二种方案是序贯 SIRT 联合系统治疗。肿瘤大小从 20.2cm×19.8cm 显著缩小至 16.2cm×13.8cm,然后依次缩小至 7.8cm×6.8cm。同时,剩余肝体积与全肝体积的比值从 34.4%逐渐增加至 55.7%,然后增加至 62.9%。此外,门静脉显影,提示肿瘤血栓退缩。最终,由于左外侧叶出现新肿瘤,患者未行切除术而行 LT,无重大并发症。
无法手术的巨大 HCC 伴 PVTT 患者可先转化为 SIRT,然后序贯接受手术。